Aries Wealth Management bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, Holdings Channel reports. The fund bought 4,074 shares of the medical research company’s stock, valued at approximately $870,000.

Other institutional investors also recently made changes to their positions in the company. Bank of Nova Scotia Trust Co. acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth $106,000. Ropes Wealth Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 97 shares in the last quarter. Atlantic Trust LLC purchased a new position in shares of Thermo Fisher Scientific during the second quarter valued at $138,000. Acrospire Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 66.7% during the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock valued at $174,000 after buying an additional 400 shares in the last quarter. Finally, Glassman Wealth Services grew its holdings in shares of Thermo Fisher Scientific by 23.1% during the second quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock valued at $181,000 after buying an additional 195 shares in the last quarter. 86.31% of the stock is currently owned by institutional investors.

In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 33,327 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $219.70, for a total value of $7,321,941.90. Following the completion of the sale, the senior vice president now owns 60,471 shares of the company’s stock, valued at $13,285,478.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the sale, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The disclosure for this sale can be found here. Insiders sold 139,327 shares of company stock worth $27,633,742 in the last 90 days. Corporate insiders own 0.49% of the company’s stock.

A number of brokerages have recently weighed in on TMO. Barclays lifted their price target on Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Leerink Swann reiterated an “outperform” rating and set a $239.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Thursday, February 1st. They noted that the move was a valuation call. Bank of America lifted their price target on Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, February 1st. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price target on the stock in a report on Tuesday, October 31st. Finally, Morgan Stanley lifted their price target on Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Two analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average price target of $220.50.

Thermo Fisher Scientific Inc. (NYSE:TMO) opened at $207.55 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.35 and a quick ratio of 0.92. Thermo Fisher Scientific Inc. has a 52 week low of $151.69 and a 52 week high of $226.44. The company has a market capitalization of $82,790.00, a PE ratio of 37.06, a price-to-earnings-growth ratio of 1.53 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the previous year, the company posted $2.41 earnings per share. The business’s quarterly revenue was up 22.1% compared to the same quarter last year. equities research analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s payout ratio is 10.71%.

COPYRIGHT VIOLATION WARNING: “4,074 Shares in Thermo Fisher Scientific Inc. (TMO) Purchased by Aries Wealth Management” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/02/08/4074-shares-in-thermo-fisher-scientific-inc-tmo-purchased-by-aries-wealth-management.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.